Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO) (HF974016)

Name: Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO)
Brand: abinScience
SKU: HF974016
Price: 176 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HF974016
설명	Apolizumab (HF974016) is a research-grade recombinant antibody targeting HLA class II histocompatibility antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG1-nd
발현 시스템	Mammalian cells
타겟	HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1
내독소 수준	< 10 EU/mg
순도	>95% purity as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P01911
형태	Liquid
저장 완충액	0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	Hu1D10, 267227-08-7
배경	HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) is a ~29 kDa protein. A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Schulze zur Wiesch, J. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 3603-13. PMID: 16148104 3. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 4. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 5. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 6. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 7. Topalian, SL. et al. (1996) The Journal of experimental medicine 183, 1965-71. PMID: 8642306 8. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 9. Schmid, D. et al. (2007) Immunity 26, 79-92. PMID: 17182262
참고사항	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)